Q-omics provides the consensus-scored YTHDC1 profile across patient tissues and cancer cell-line models. YTHDC1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, YTHDC1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, YTHDC1 protein abundance shows 29,991 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where YTHDC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YTHDC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YTHDC1 survival associations across molecular data types. YTHDC1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YTHDC1 RNA expression–survival associations across cancer types. High YTHDC1 expression shows unfavorable associations in ACC, but favorable associations in KIRC, UCS, BRCA, HNSC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for YTHDC1 RNA expression.
This table summarizes YTHDC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for YTHDC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YTHDC1 shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in LIHC, CHOL and HNSC. The THCA box plot shows higher YTHDC1 RNA expression in normal versus tumor tissue (log2 FC = −0.652, t-test p < 0.001).
This table shows molecular features associated with YTHDC1 in patient tissues and cancer cell lines. In patient samples, YTHDC1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, YTHDC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
